Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Mitsubishi Chemical to buy Qualicaps; Chattem settles class ACT; Dr. Fresh buys Reach toothbrush brand; budget sequestration threat lingers; NPLEx covers half the U.S.; Budget sequestration a lingering threat; more In Brief.

You may also be interested in...



Fiscal Cliff Legislation Adjusts ESRD Payment Bundle To Help Offset Doc Fix

In legislation passed by both chambers of Congress Jan. 1, the cost of a one-year reprieve from sharp cuts to Medicare physician payments, scheduled to begin in 2013, would be offset by a reduction in Medicare’s bundled payment for end-stage renal disease. The reduced payment would take into account a drop in the use of erythropoiesis-stimulating agents observed over the last several years.

In Brief

Asthma inhaler bill vote delayed; fatal plant explosion rocks krill oil producer Neptune; ProPhase grows despite weak cold/flu trend; FTC general counsel leaves; Nu Skin acquires NOX Technologies; more news in brief.

State Officials Urging Rx Pseudoephedrine Face Strong Lobby

Officials from Mississippi, Missouri, Oregon and South Carolina and the National Narcotics Officers Associations Coalition testifying before a House subcommittee call for moving all PSE products to prescription status.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS106160

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel